AlphAIalphai — Financial news for AI agents
SEC EDGARJUL 61 min read$NTLA

Dulac Edward J III sold $84K of NTLA

Dulac Edward J III (EVP, Chief Financial Officer) sold 4,677 shares of Intellia Therapeutics, Inc. (NTLA) at $18.00 on 2026-07-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Dulac Edward J III
Published Jul 6, 2026, 9:01 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 6, 2026, 9:05 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$NTLA
Neutral
medium confidence
Mentioned
$NTLA
Relevance
2/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTLANeutralLow
01

Why it matters

For trading, the key takeaway is disclosure of insider liquidity/diversification rather than a new operational or financial development.

02

Market read

Discloses a specific insider sale (4,677 shares at $18.00) with post-transaction holdings of 156,286 shares.

03

What to watch

The sale size ($84K) is modest relative to typical institutional flows; without additional context (e.g., multiple concurrent insider sales), the signal is weak.

Relevance 2/10Novelty 3/10Timing: Filed on 2026-07-06 after the 2026-07-02 sale execution.

Background

The filing is an SEC Form 4 insider transaction by the company’s CFO, executed under a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$NTLANeutralMedium confidence
Context

Intellia Therapeutics CFO Dulac Edward J III sold 4,677 shares on a 10b5-1 plan for about $84.2K at $18.00/share.

Expected impact

Likely minimal near-term impact; any effect would be sentiment-only and typically short-lived.

Evidence & confidence

Form 4 insider sales can be interpreted as diversification, and the filing explicitly states a pre-arranged 10b5-1 plan, reducing signal strength versus discretionary selling.

Market effects

Sector

No clear sector read-through; this is company-specific insider transaction data.

Regional

None.

Global

None.

Counterpoint

What could challenge this read

Even with a 10b5-1 plan, repeated insider selling can coincide with internal expectations of near-term risk, so traders may watch for follow-on disclosures.

Key entities

  • issuer
    Intellia Therapeutics, Inc.

    Subject of the Form 4 insider sale by its CFO.

  • insider
    Dulac Edward J III

    EVP and Chief Financial Officer who sold shares under a 10b5-1 plan.

Read at source← All news

Related articles

AUG 7
$NTLAMedAI 8/10

Intellia Therapeutics Q2 2026 Earnings: Revenue Misses $7.7 Million

Intellia Therapeutics (Nasdaq: NTLA) reported Q2 2026 EPS of -$0.80, in line with consensus, but collaboration revenue fell to $7.7 million versus an estimated ~$13.0 million. Net loss was $106.6 million. The company said Phase 3 HAELO data for lonvo-z reduced attacks by 87% and expects lonvo-z BLA acceptance in H2 2026 and a U.S. launch in H1 2027. Cash was $628.4 million.

sci-tech-today.com7 min
AUG 6
$NTLAHigh

Intellia Therapeutics, Inc. (NTLA): Results of Operations and Financial Condition

Intellia Therapeutics, Inc. (NTLA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ntla-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates - Positive Phase 3 HAELO clinical data for lonvo-z in HAE presented at EAACI and published in New England Journal of Medicine - Antici

SEC EDGAR 8-K7 min
AUG 6
$NTLAMedAI 8/10

Intellia Therapeutics, Inc.: Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates

Intellia Therapeutics (Nasdaq: NTLA) reported Q2 2026 results and updates. It said Phase 3 HAELO data for lonvo-z in hereditary angioedema met primary and key secondary endpoints, with an 87% attack reduction vs placebo. Intellia expects FDA BLA acceptance in H2 2026 and a U.S. launch in H1 2027. Cash was $628.4M, funding operations into 2028.

finanznachrichten.de6 min
JUN 19
$SPROMed

Weekly Buzz: SPRO, ABBV Get FDA Nod, NMRA Halts KOASTAL; ENGN Cuts Jobs; BIIB Acquires RayThera

Biotech news roundup: Spero (SPRO) and GSK won FDA approval for Utebzi (tebipenem pivoxil) for complicated UTIs; AbbVie (ABBV) expanded FDA approval of SKINVIVE by JUVÉDERM to neck lines; Cuprina (CUPR) received 510(k) clearance for MEDIFLY maggots. Neumora (NMRA) halted KOASTAL Phase 3 and plans 35% layoffs; enGene (ENGN) cuts ~50%. Biogen (BIIB) agreed to buy RayThera for up to $1B.

rttnews.com6 min
JUN 16
$RGNTMedAI 8/10

Top Biotech Gainers: RGNT Withdraws F-1 Filing, FDA Clears CUPR's Maggot Therapy, MYO On Watch

Regentis (RGNT) shares rose 526.7% after it withdrew a planned SEC Form F-1 for a firm-commitment offering of 3.33M shares at an assumed $3.00. Cuprina (CUPR) jumped 111.8% after FDA clearance for MEDIFLY maggots for debridement of non-healing wounds. Intellia (NTLA) gained 23.2% on additional Phase 3 results for hereditary angioedema; it targets approval and a 1H 2027 launch.

rttnews.com6 min
JUN 15
$NTLAMedAI 8/10

Intellia Reports Phase 3 HAELO Trial Met Key Secondary Endpoints; BLA Response Expected In H1 2027

Intellia Therapeutics said Phase 3 HAELO trial results for Lonvo-z (lonvoguran ziclumeran) met key secondary endpoints in hereditary angioedema. The company reported 89% fewer patients needing on-demand treatment, 91% mean reduction in moderate/severe attacks, and a 17.04-point AE-QoL improvement. It also cited generally mild adverse events. A rolling BLA began April 2026; FDA response expected H1 2027.

rttnews.com5 min